Page 7 - Torrent Pharma

Cipla tweaks management structure to mobilise second level of executives

Do these changes augur well for the future business growth plans? Analysts think so

Torrent Pharma leaps 10%, nears 52-wk high as Q1 net profit jumps 49% YoY

In terms of markets, while its India revenues grew marginally by 2% on a year-on-year (YoY) basis to Rs 925 crore, up from Rs 907 crore in Q1 of FY20, its US revenues fell by 1% to Rs 373 crore

Torrent Pharma Q1 PBT up 44% to Rs 402 cr, income rises marginally

Domestic and US market revenues more or less flat, 20% drop in Brazilian revenues

Torrent Pharma slips 6% on profit-booking; outlook remains a concern

Unlike peers, Torrent Pharma guided for a relatively moderate outlook across geographies, note analysts at Emkay Global Financial Services.

Torrent Pharma posts Q4FY20 PBT of Rs 293 cr, consolidated revenue up 4.69%

The company saw its total consolidated revenue in Q4FY20 at Rs 1961 crore, up by a marginal 4.69 per cent over Rs 1873 crore in Q4FY19

Market Ahead, May 26: Top factors that could guide markets this week

Corporate results will continue to pour in throughout the week. Investors will first react to HDFC's and other results that were announced over the weekend

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India growth crucial for Torrent Pharma's health amid steep fall in volume

The country accounts for 44% of overall revenues

Torrent Pharma gets shareholder nod to raise up to Rs 5,000 crore

The approval of the shareholders was sought by way of special resolution through a postal ballot

Derivatives strategy on Torrent Pharmaceuticals by HDFC Securities

Derivative strategy on Pidilite Industries by Vinay Rajani -Technical and Derivatives analyst, HDFC Securities.

Subdued Q3 performance leads to stock correction in Torrent Pharma

While analysts expect India growth to rebound, regulatory overhang may continue

USFDA red flags Torrent Pharma's US-based arm for manufacturing violations

The plant's water system was not adequately designed, controlled, maintained, and monitored to ensure it consistently produced water that met specifications and appropriate microbial limits

Top stock picks by CapitalVia: Buy Adani Green Energy, Torrent Pharma

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Torrent Pharma Q1 net up 33% to Rs 216 cr as thrust on Unichem biz pays off

Consolidated revenue up 7.5% to Rs 2,042 crore; India biz grwis 9%, US revenues up 13%

Stocks to watch: PSU banks, ACC, DB Corp, L&T Infotech, Wipro, Mindtree

Here's a look at the top counters that are likely to trade actively in today's session.

India operations to offset challenges in US market for Torrent Pharma

Further correction in stock could present a buying opportunity

Torrent Pharma reports Q4 net loss of Rs 152 crore, cites drug recall

Pharma company says it faced one-time impact of the recall hypertension drug in the US market.

Low US exposure makes Torrent Pharma a safe bet among drug firms

Torrent has successfully gained volume share and demonstrated its ability to take price increases

Slow growth of Unichem business portfolio a concern for Torrent Pharma

India revenue of the pharmaceutical firm has remained flat over the past three quarters

Torrent Pharma records over four-fold jump in Q3 profit at Rs 246 crore

Consolidated revenue from operations stood at Rs 2,051 crore for the quarter, against Rs 1,463 crore a year ago